Galderma has received filing acceptances for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland and the United Kingdom, the company ...

Galderma has announced positive data from three phase 3 studies that evaluated nemolizumab for the treatment of atopic dermatitis and prurigo nodularis, according to a company press release ...

The approval stipulates use in adults with prurigo nodularis, a skin condition characterized by chronic itch, nodules covering large areas of the body, and poor sleep quality. Driven by IL-31 ...

Nemolizumab provides significant relief from itch and skin lesions in prurigo nodularis and atopic dermatitis, with sustained efficacy over two years. The biologic targets the interleukin-31 ...

Galderma has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia ...

In Japan, nemolizumab is approved for the treatment of pruritus associated with atopic dermatitis and is in development for prurigo nodularis.

"PN is a chronic dermatosis of unknown etiology characterized by discrete, intensely pruritic, symmetric, papulo-nodular lesions primarily on the extensor surfaces of the extremities.